Clinical trial
A Phase 1 Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 (Part 1) and a Multiple Dose, Placebo-controlled Exploratory Safety, Pharmacokinetic and Pharmacodynamic Study in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease (Part 2)
NCT02218099 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 (Part 1) and a Multiple Dose, Placebo-controlled Exploratory Safety, Pharmacokinetic and Pharmacodynamic Study in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease (Part 2)
- Lead sponsor
- Astellas Pharma Europe B.V.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 16, 2013
- Completion date
- September 9, 2014
- Enrollment
- 55 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
chronic kidney disease (ckd), healthy subjects, pharmacodynamics of asp8232, pharmacokinetics of asp8232, type 2 diabetes mellitus (t2dm)